Your browser doesn't support javascript.
loading
Antibiotic treatment for patients with exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Suzuki, Yasuhito; Sato, Kento; Sato, Suguru; Inoue, Sumito; Shibata, Yoko.
Afiliação
  • Suzuki Y; Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima, 960-1295, Japan.
  • Sato K; Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, 2-2-2 Iida-Nishi, Yamagata-City, Yamagata, 990-9585, Japan.
  • Sato S; Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima, 960-1295, Japan.
  • Inoue S; Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine, 2-2-2 Iida-Nishi, Yamagata-City, Yamagata, 990-9585, Japan.
  • Shibata Y; Department of Pulmonary Medicine, Fukushima Medical University School of Medicine, 1 Hikarigaoka, Fukushima City, Fukushima, 960-1295, Japan. Electronic address: shibatay@fmu.ac.jp.
Respir Investig ; 62(4): 663-668, 2024 Jul.
Article em En | MEDLINE | ID: mdl-38761481
ABSTRACT

BACKGROUND:

Although respiratory tract infection is a significant factor that triggers exacerbation of chronic obstructive pulmonary disease (COPD), the benefit of antibiotics for patients with COPD exacerbation remains controversial. It is necessary to evaluate the efficacy and safety of antibiotics versus placebo in such patients.

METHODS:

We conducted a systematic review and meta-analysis of randomized controlled trials of antibiotics versus placebo for the treatment of COPD exacerbation, and compared the frequencies of treatment failure, mortality, and adverse events between patients treated with antibiotics and those treated with placebo.

RESULTS:

A total of six studies were included in this meta-analysis. The frequency of treatment failure was significantly lower in the antibiotic-treated patients compared to the placebo-treated patients (odds ratios [OR] 0.50, 95% confidence intervals [CI] 0.35-0.71, p = 0.0001). There was no significant difference between the two groups in mortality (OR 0.44, 95% CI 0.05-3.76, p = 0.45) or frequency of adverse events (OR 1.05, 95% CI 0.75-1.48, p = 0.78).

CONCLUSION:

In the current systematic review and meta-analysis, we found that antibiotics were superior to placebo in patients with exacerbated COPD, as shown by the lower treatment failure rate.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Progressão da Doença / Doença Pulmonar Obstrutiva Crônica / Antibacterianos Limite: Humans Idioma: En Revista: Respir Investig Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Progressão da Doença / Doença Pulmonar Obstrutiva Crônica / Antibacterianos Limite: Humans Idioma: En Revista: Respir Investig Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Japão